1 July 2025 in Journal of Thoracic Disease
SISheila Izquierdo-Cuervo
+6
Background: Lung transplantation (LT) represents a critical therapeutic intervention for advanced chronic lung diseases. This study aims to elucidate the prognostic implications of donor-recipient size matching, specifically focusing on the ratio of predicted total lung capacity (pTLC). Methods: We conducted a retrospective cohort analysis of 380 transplant recipients at a single LT center from January 2015 to October 2023. Patients were stratified based on size discrepancies exceeding 10% and 20%, calculated using two established formulas. Results: Our findings indicate that significant size mismatches do not correlate with adverse post-transplant outcomes, including primary graft dysfunction (PGD), duration of mechanical ventilation, or overall survival rates. Notably, a size discrepancy greater than 20% utilizing the first formula emerged as an independent risk factor for the composite outcome of chronic lung allograft dysfunction (CLAD) and mortality. While the majority of donor-recipient pairings were of the same sex, sex mismatch significantly influenced size discrepancies. Furthermore, chronic obstructive pulmonary disease (COPD) patients demonstrated elevated pTLC ratios compared to those with interstitial lung disease (ILD), underscoring the complexity inherent in size matching across different pathologies. Conclusions: Our data suggests that significant size discrepancies between donor and recipient do not adversely impact immediate outcomes in LT recipients, but it may have significant long-term implications; therefore, appropriate donor size selection for each recipient is essential. The use of pTLC formulas can be helpful for estimating the suitable size.
1 October 2022 in Pulmonary Circulation
In pulmonary arterial hypertension (PAH) patients it is essential to perform a prognostic assessment to optimize the treatment. The aim of this study is to evaluate the risk stratification concordance assessed with different exercise test variables in a cohort of PAH patients. A retrospective analysis was performed using patient data registered in the PAH unit. Only those patients in whom the mean time elapsed between the 6‐min walking test (6MWT) and the cardiopulmonary exercise test (CPET) was a maximum of 6 months were selected. A total of 140 records from 40 patients were finally analyzed. When it came to assessing the concordance between the two exercise tests in the guidelines (CPET and 6MWT), up to 84.3% of the records did not coincide in terms of the risk stratification. Exclusively considering the CPET parameters, most of the records (75%) failed to include all three variables in the same risk category. When analyzing the VO2 alone, up to 40.7% of the tests yielded different risk classifications depending on whether the parameter was expressed. In conclusion, there is a low concordance between the two proposed exercise tests. These results should be a call for reflection on whether the cut‐off points set for the exercise tests proposed for the current risk stratification are adequate to achieve a correct risk stratification or whether they require an appropriate revision.
1 January 2024 in Pulmonary Circulation
A simplified 4‐strata risk stratification approach based on three variables is widespread in pulmonary arterial hypertension (PAH) at follow‐up. This study aimed to assess the impact of replacing the 6‐min walk test (6MWT) with the peak 02 uptake evaluated by the cardiopulmonary exercise test (CPET) on risk stratification by this scale. We included 180 prevalent patients with PAH from two reference hospitals in Spain, followed up between 2006 and 2022. Patients were included if all the variables of interest were available within a 3‐month period on the Spanish Registry of Pulmonary Arterial Hypertension (REHAP): functional class (FC); NT‐proBNP; 6MWT; and CPET. The original 4‐strata model (NT‐proBNP, 6MWT, FC) identified most patients at low or intermediate‐low risk (36.7% and 51.1%, respectively). Notably, the modified scale (NT‐proBNP, CPET, FC) improved the identification of patients at intermediate‐high risk up to 18.9%, and at high risk up to 1.1% in comparison with the previous 12.2% and 0.0% in the original scale. This new model increased the number of patients correctly classified into higher‐risk strata (positive NRI of 0.06), as well as classified more patients without events in lower‐risk strata (negative NRI of 0.04). The proposed score showed a slightly superior prognostic capacity compared with the original model (Harrel's C‐index 0.717 vs. 0.709). Using O2 uptake instead of distance walked in the 6MWT improves the identification of high‐risk patients using the 4‐strata scale. This change could have relevant prognostic implications and lead to changes in the specific treatment of PAH.
6 March 2021 in Advances in Therapy
31 July 2025 in ERJ Open Research
Aims: Toxic oil syndrome (TOS) was one of the first described forms of drug-induced pulmonary arterial hypertension (PAH). Its long-term clinical evolution remains poorly understood. The objectives of the present study were to provide new clinical, pathological and genetic insights into TOS-associated PAH (TOS-PAH), and to evaluate its long-term outcomes. Methods: Patients diagnosed with TOS-PAH and included in the Spanish Registry of PAH (REHAP) were prospectively analysed. Results: 59 new cases were diagnosed between 1997 and 2025 (63% female; median age 47 years), including several in the past two decades. The median interval between TOS exposure and PAH diagnosis was 270.8 months (interquartile range (IQR) 204.9–398.0). Patients diagnosed in earlier periods were younger, with more advanced functional impairment and more severe haemodynamics. In contrast, recent cohorts showed a higher prevalence of cardiovascular and respiratory comorbidities. No significant differences were observed in overall or transplant-free survival across decades (p=0.677). Median transplantation-free survival was 97.2 months (IQR 64.2–199.4). Three patients achieved complete haemodynamic resolution. Genetic testing was negative in all evaluated patients. Pathological findings were comparable with those observed in other PAH forms, with some cases with significant venous remodelling. Conclusions: TOS-PAH remains a distinct clinical entity, with new cases diagnosed decades after toxic exposure. Despite differences in presentation over time, its long-term clinical course appears similar to that of other PAH types.
1 October 2026 in ERJ Open Research
Background: Pulmonary hypertension (PH) is frequent and impactful in respiratory disease, but its characteristics in the Spanish population are unknown. We aimed to describe the clinical features and outcomes of patients with PH associated with COPD, interstitial lung disease (ILD) and combined pulmonary fibrosis and emphysema (CPFE). Methods: We analysed patients enrolled in the Spanish Registry of PH Associated with Respiratory Disease (REHAR) from January 2002 to December 2024. Baseline characteristics, haemodynamics, and outcomes were compared across groups and according to severity using the 6th World Symposium on PH (6WSPH) and the 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) 2022 guidelines. Results: Among 434patients, 216 had COPD, 173 had ILD and 45 had CPFE. Severe PH was associated with worse hypoxaemia in all groups. Survival was poorer in ILD and CPFE compared with COPD (p=0.017). In COPD and CPFE, survival was worse in severe PH versus nonsevere PH, using both the 6WSPH (p=0.048 and p=0.021) and the ESC/ERS criteria (p=0.005 and p=0.027). In ILD, neither classification predicted survival (p=0.086 and p=0.270) and no pulmonary vascular resistance threshold discriminated outcomes. Comparing classifications, 31% of patients changed severity category, with reclassified patients showing distinct clinical profiles. Conclusions: This study highlights important clinical differences among Spanish patients with COPD, ILD and CPFE. Haemodynamic compromise had a variable impact on survival across diseases, underscoring the heterogeneity of group 3 PH and the need for disease-specific approaches.